Last reviewed · How we verify

ASKP1240 — Competitive Intelligence Brief

ASKP1240 (ASKP1240) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PI3Kδ inhibitor. Area: Oncology.

phase 2 PI3Kδ inhibitor PI3Kδ Oncology Small molecule Live · refreshed every 30 min

Target snapshot

ASKP1240 (ASKP1240) — Astellas Pharma Global Development, Inc.. ASKP1240 is a small molecule inhibitor of the PI3Kδ enzyme.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ASKP1240 TARGET ASKP1240 Astellas Pharma Global Development, Inc. phase 2 PI3Kδ inhibitor PI3Kδ
IPI-145 IPI-145 SecuraBio phase 3 PI3K delta/gamma inhibitor PI3K delta (PI3Kδ), PI3K gamma (PI3Kγ)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PI3Kδ inhibitor class)

  1. Astellas Pharma Global Development, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ASKP1240 — Competitive Intelligence Brief. https://druglandscape.com/ci/askp1240. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: